Type 2 diabetes mellitus
Conditions
Interventions
Ramulus Mori (Sangzhi) alkaloids (SZ-A) group:None
Acarbose group:None
Sponsors
Hunan University of Medicine General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients who visited the endocrinology outpatient or inpatient department at Hunan University of Medicine General Hospital from January 2023 to December 2025, and were diagnosed with type 2 diabetes (according to the 1999 WHO criteria); 2. Aged 18–80 years, any gender; 3. Records of body composition/visceral fat measurements (using the same model equipment) available at baseline and 24 weeks (+/- weeks) after medication; 4. Mulberry branch total alkaloid group: continuously used mulberry branch total alkaloid tablets (50 mg three times daily) for >=24 weeks, with complete records before and after medication; Acarbose group: continuously used acarbose tablets (50 mg three times daily) for >=24 weeks; both groups may be combined with metformin (stable dose), and may be combined with other non-a-glucosidase inhibitor hypoglycemic drugs (stable for >=12 weeks); 5. Complete medical records, including key indicators required for the study (HbA1c, blood lipids, uric acid, etc.).
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes, gestational diabetes, or other specific types of diabetes; 2. Switched a-glucosidase inhibitors during medication (e.g., from acarbose to SZ-A, or vice versa), or poor medication compliance (explicitly documented discontinuation or switching in medical records); 3. Complicated with severe heart, liver, or kidney dysfunction (NYHA class III/IV, ALT/AST > 2.5×ULN, eGFR < 60 ml/min), malignant tumors, or major surgery or trauma; 4. Pregnant or breastfeeding women; 5. Currently using weight-affecting drugs such as weight-loss medications or systemic corticosteroids; 6. Key data missing (e.g., baseline VFA or 24-week VFA missing).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visceral fat area ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body composition parameters (skeletal muscle mass, body fat percentage, subcutaneous fat area);General data and endocrine and metabolic-related indicators; | — |
Countries
China
Contacts
Public ContactShaolin Peng
Hunan University of Medicine General Hospital
Outcome results
None listed